BenevolentAI vs Exscientia

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. BenevolentAI employs 100-500 people, while Exscientia has 100-500 employees.

Exscientia has raised more in total funding at $500M, compared to BenevolentAI's $292M — a gap of $208M.

Exscientia holds the higher Awaira Score at 72/100, compared to BenevolentAI's 62/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 10-point gap that reflects meaningful differences in scale or traction.

BenevolentAI was founded by Joanna Shields in 2013. Exscientia was founded by Andrew Hopkins in 2012. Visit each company's profile on Awaira for a full founder biography.

BenevolentAI: BenevolentAI applies machine learning to drug discovery, using knowledge graph technology and predictive AI models to identify novel drug candidates and repurpose existing compounds for new therapeutic applications. The London-based company has built a proprietary biomedical knowledge graph containing billions of data points extracted from scientific literature, clinical trial data, and genomic databases, which feeds its target identification and molecule generation pipelines.\n\nThe company went public on Euronext Amsterdam in 2022 via a SPAC merger with Odyssey Acquisition, having previously raised approximately $292 million in private funding from backers including SoftBank, Woodford Investment Management, and Mayfair Equity Partners. BenevolentAI has clinical-stage programs in atopic dermatitis and amyotrophic lateral sclerosis, developed from AI-generated hypotheses that were subsequently validated in wet lab experiments and progressed into human trials.\n\nBenevolentAI operates in the AI drug discovery sector alongside Recursion Pharmaceuticals, Exscientia, and Insilico Medicine. The company faces the inherent challenge of all computational drug discovery platforms in demonstrating that AI-generated candidates can survive clinical attrition at higher rates than traditionally discovered drugs. The platform is considered one of the more mature AI drug discovery systems in Europe, with the longest track record of moving AI-generated hypotheses into clinical development. Exscientia: Exscientia is an AI-driven drug design company that uses automated design-make-test-analyse cycles to generate drug candidates with the goal of reducing the time and cost of small molecule drug discovery. The Oxford-originated company builds generative chemistry models and automated laboratory robotics that together create a closed-loop system for molecular design, synthesis, and assay testing, producing candidates in months rather than the years required by conventional medicinal chemistry programmes.\n\nThe company went public on NASDAQ under the ticker EXAI, having raised over $500 million in combined public and private funding from investors including Bristol-Myers Squibb, Celgene, SoftBank, and GT Healthcare Capital Partners. Exscientia has clinical-stage programmes in oncology and neuropsychiatry and reports being the first company to advance AI-designed drug candidates into human clinical trials. The company has multiple pharma partnerships including agreements with Bristol-Myers Squibb, Sanofi, and Evotec that provide milestone and royalty revenue.\n\nExscientia competes in the AI drug design space against Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics, and Insilico Medicine. The company differentiates through its integrated automated laboratory approach, which combines computational design with physical synthesis and testing in a single workflow rather than treating AI design as a separate step before conventional chemistry. Its public market position and disclosed clinical programmes provide transparency benchmarks against which the broader AI drug discovery sector is measured by investors and pharmaceutical partners.

Exscientia was founded first in 2012, giving it 1 year of additional market experience. BenevolentAI was founded later in 2013. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Both BenevolentAI and Exscientia report similar employee counts of approximately 100-500. Team size is often a proxy for operational scale, though lean AI companies can punch well above their headcount.

Yes, BenevolentAI and Exscientia are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.